LBP-045 Efficacy and safety of HSK31679, a thyroid hormone receptor β agonist, for the treatment of asian non-alcoholic fatty liver disease: a multicenter randomized, double-blind, placebo-controlled, phase 2a trial
Xue Feng, Lai Wei(Changchun Obstetrics and Gynecology Hospital), Le Wang, Peili Bu(Shandong University), Fei Liu, Kunyan Hao, Lingchun Lv(Zhejiang Chinese Medical University), Yanhang Gao(Jilin University), Wei Yue, Zhaohui Pei, Ying Chen, Qincong Chen, Bihua Xia, Bihui Zhong(Sun Yat-sen University), Yong Huo(Sun Yat-sen University), Liang Chen(University of North Carolina at Chapel Hill), Chuanwu Zhu(The Fifth People’s Hospital of Suzhou), Jianming Zhang, Wei Ma(The Affiliated Yongchuan Hospital of Chongqing Medical University), Guangming Li(The Sixth People's Hospital of Zhengzhou), Hao Chen(Hohai University), Yang Liu(Guiyang College of Traditional Chinese Medicine), Qingxian Cai, Laijing Du(First Affiliated Hospital of Henan University of Science and Technology), Jinjun Chen(Southern Medical University), Genshan Ma(Zhongda Hospital Southeast University), Jixian Gao(Zhengzhou University), Jianlong Sheng, Xianyou Ji, Lvfeng Yao
Cited by 27
Related Papers
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
|The Lancet|2017|1.3k
World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI
|Nature Reviews Cardiology|2014|339